What is Avalo Therapeutics's financing cash flow?

Avalo Therapeutics (AVTX) reported financing cash flow of $1.4M in Q1 2026.

What is the long-term trend for Avalo Therapeutics's financing cash flow?

Over 2 years (2021 to 2025), Avalo Therapeutics's financing cash flow has grown at a -63.0% compound annual growth rate (CAGR), from $106.76M to $14.59M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Avalo Therapeutics AVTX Financing Cash Flow

Financing Cash Flow at other companies

Eli LillyLLY

-$3.47B-351%

AbbVieABBV

$919M+173%

XencorXNCR

$950K-23.9%

AbCellera Biologics Inc.ABCL

$7.19M+20.5%

AnaptysBio, Inc.ANAB

$1.21M+104%

Absci CorporationABSI

$7.56M-82.3%

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's financing cash flow?: Avalo Therapeutics (AVTX) reported financing cash flow of $1.4M in Q1 2026.
What is the long-term trend for Avalo Therapeutics's financing cash flow?: Over 2 years (2021 to 2025), Avalo Therapeutics's financing cash flow has grown at a -63.0% compound annual growth rate (CAGR), from $106.76M to $14.59M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.